• All
• March 28 (Thursday)
• March 29 (Friday)
• March 30 (Saturday)

Day-2 - March 29 (Friday)

• Pediatric and AYA ALL: Lessons learned from children’s oncology group clinical trials Sarah K. Tasian
  The Children’s Hospital of Philadelphia, USA CV Abstract
• Multicenter trials investigating childhood acute lymphoblastic leukemia in South Korea Hyery Kim
  University of Ulsan College of Medicine, Korea CV Abstract
• Dissecting the developmental origins of acute leukemia Charles G. Mullighan
  St. Jude Children’s Research Hospital, USA CV Abstract
• Unveiling precision medicine: RNA and DNA sequencing in targeted therapy for Korean pediatric leukemia Myungshin Kim
  The Catholic University of Korea College of Medicine, Korea CV Abstract

Day-2 - March 29 (Friday)

• Comprehensive overview of cell-based artificial platelet production Seung Yeob Lee
  Jeonbuk National University Medical School, Korea CV Abstract
• Anti-CD38 and anti-CD47 delay timely transfusion Hyungsuk Kim
  Seoul National University College of Medicine, Korea CV Abstract
• Reappraisal of transfusion-transmitted infections Dae-Hyun Ko
  University of Ulsan College of Medicine, Korea CV Abstract

Day-2 - March 29 (Friday)

• Clonal hematopoiesis and aging Siddhartha Jaiswal
  Stanford University School of Medicine, USA CV Abstract
• Clonal hematopoiesis: Implications for cell therapy Adam S. Sperling
  Dana-Farber Cancer Institute, USA CV Abstract
• Clonal hematopoiesis and metabolic diseases Sung Hee Choi
  Seoul National University College of Medicine, Korea CV Abstract

Day-2 - March 29 (Friday)

• The impact of immune profiling of T-cell and plasma cells on non-cellular immune therapy in myeloma Nizar Jacques Bahlis
  University of Calgary, Canada CV Abstract
• Single-cell techniques to characterize immune microenvironment in MM Niels Weinhold
  Heidelberg University, Germany CV Abstract
• The power of ONE: Immunology in the age of single cell genomics Ido Amit
  Weizmann Institute of Science, Israel CV Abstract

Day-2 - March 29 (Friday)

• How to win: Competitive strategies in the hematopoietic stem cell niche Margaret Goodell
  Baylor College of Medicine, USA CV Abstract

Day-2 - March 29 (Friday)

• Continued Hope with ONUREG - A New Maintenance therapy to treat AML Esther Oliva
  Grande Ospedale Metropolitano Bianchi Melacrino Morelli, Italy CV Abstract

Day-2 - March 29 (Friday)

• Mogamulizumab: A new era in MF/SS management - Clinical evidence and practical consideration Francine Foss
  Yale University School of Medicine, USA CV

Day-2 - March 29 (Friday)

• TKI treatment pattern and new therapy of CML Qian Jiang
  Peking University People's Hospital, China CV Abstract

Day-2 - March 29 (Friday)

• The optimal treatment strategy for transplant-ineligible relapsed/refractory DLBCL Kwai Han Yoo
  Gachon University College of Medicine, Korea CV Abstract

Day-2 - March 29 (Friday)

• The journey of bone marrow transplantation at BachMai General Hospital Han Viet Trung
  Bach Mai Hospital, Vietnam CV Abstract
• Current situation of management of Non-Hodgkin lymphoma in the Republic of Armenia Yervand Hakobyan
  Armenian Hematology Association, Armenia CV Abstract
• The evolution of hemophilia treatment in Thailand Darintr Sosothikul
  Chulalongkorn University, Thailand CV Abstract

Day-2 - March 29 (Friday)

• Palliative care for patients with leukemia Min Sun Kim
  Seoul National University College of Medicine, Korea CV Abstract
• Long-term survivorship in hematologic malignancies Shahrukh K. Hashmi
  Mayo Clinic, UAE CV Abstract
• The importance of monitoring symptoms and quality of life in routine hematology practice Fabio Efficace
  Italian Group for Adult Hematologic Diseases, Italy CV Abstract

Day-2 - March 29 (Friday)

• Novel approaches for diagnosis & treatment of acute lymphoblastic and myeloid leukemia Michel Zwaan
  Princess Máxima Center for Pediatric Oncology, The Netherlands CV Abstract
• The role of blinatumomab in the treatment of MRD negative B-ALL in adults Mark R. Litzow
  Mayo Clinic, USA CV Abstract
• Revised WHO classification of ALL: New era of genetic diagnosis Ari Ahn
  The Catholic University of Korea College of Medicine, Korea CV Abstract

Day-2 - March 29 (Friday)

• AL cardiac amyloidosis Darae Kim
  Sungkyunkwan University School of Medicine, Korea CV Abstract
• Nephrologist’s perspective on monoclonal gammopathy of renal significance Soon Hyo Kwon
  Soonchunhyang University College of Medicine, Korea CV Abstract
• Monoclonal gammopathies of neurological significance Ju-Hong Min
  Sungkyunkwan University School of Medicine, Korea CV Abstract

Day-2 - March 29 (Friday)

• Clonal evolution of MDS/AML in patients with cancer predisposition syndromes Kenichi Yoshida
  National Cancer Center Research Institute, Japan CV Abstract
• Congenital and acquired thrombophilia in children Leonardo R. Brandão
  University of Toronto, Canada CV Abstract
• Management of rare pediatric lymphomas Jae Wook Lee
  The Catholic University of Korea College of Medicine, Korea CV Abstract

Day-2 - March 29 (Friday)

• Epidemiology, risk stratification and treatment outcome in acute myeloid treatment: Taiwan experience Hsin-An Hou
  National Taiwan University, Taiwan CV Abstract
• Advancement in leukaemia diagnostics: The role of next-generation sequencing (NGS) in acute myeloid leukaemia in Malaysia Angeli Ambayya
  Ministry of Health, Malaysia CV Abstract
• Determining fitness for treatments in older adults with AML Byung Sik Cho
  The Catholic University of Korea College of Medicine, Korea CV Abstract

Day-2 - March 29 (Friday)

• Back to the basic: Coagulation pathway Seonyang Park
  Inje University College of Medicine, Korea CV Abstract
• Pharmacology: Anticoagulants and reversal agents Seo-Yeon Ahn
  Chonnam National University Medical School, Korea CV
• Proper application of anticoagulation therapy on cancer associated thrombosis Ho-Young Yhim
  Jeonbuk National University Medical School, Korea CV